Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention

Authors: Mao-Jen Lin, Chun-Yu Chen, Hau-De Lin, Han-Ping Wu

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

Percutaneous coronary intervention (PCI) is a necessary procedure commonly performed for patients with coronary artery disease (CAD). However, the impact of diabetes and hypertension on long-term outcomes of patients after receiving PCI has not yet been determined.

Methods

The data of 1234 patients who received PCI were collected prospectively, and patients were divided into four groups, including patients with and without DM and those with either DM or hypertension alone. Baseline characteristics, risk factors, medications and angiographic findings were compared and determinants of cardiovascular outcomes were analyzed in patients who received PCI.

Results

Patients with DM alone had the highest all-cause mortality (P < 0.001), cardiovascular mortality and myocardial infarctions (MI) (both P < 0.01) compared to the other groups. However, no differences were found between groups in repeat PCI (P = 0.32). Cox proportional hazard model revealed that age, chronic kidney disease (CKD), previous MI and stroke history were risk factors for all-cause mortality (OR: 1.05,1.89, 2.87, and 4.12, respectively), and use of beta-blockers (BB) and statins reduced all-cause mortality (OR: 0.47 and 0.35, respectively). Previous MI and stroke history, P2Y12 inhibitor use, and syntax scores all predicted CV mortality (OR: 4.02, 1.89, 2.87, and 1.04, respectively). Use of angiotensin converting enzyme inhibitors (ACEI), beta-blockers (BB), and statins appeared to reduce risk of CV death (OR: 0.37, 0.33, and 0.32, respectively). Previous MI and syntax scores predicted MI (OR: 3.17 and 1.03, respectively), and statin use reduced risk of MI (OR: 0.43). Smoking and BB use were associated with repeat PCI (OR: 1.48 and 1.56, respectively).

Conclusions

After PCI, patients with DM alone have higher mortality compared to patients without DM and hypertension, with both DM and hypertension, and with hypertension alone. Comorbid hypertension does not appear to increase risk in DM patients, whereas comorbid DM appears to increase risk in hypertensive patients.

Trial registration

REC103-15 IRB of Taichung Tzu-chi Hospital
Literature
1.
go back to reference Williams DO, Abbott JD, Kip KE. DEScover investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation. 2006;114(20):2154–62.CrossRefPubMed Williams DO, Abbott JD, Kip KE. DEScover investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation. 2006;114(20):2154–62.CrossRefPubMed
2.
go back to reference Lazzeri C, Valente S, Chiostri M, Attana P, Picariello C, Gensini GF. Impact of hypertension on short and long- term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes. Heart Vessels. 2012;27(4):370–6.CrossRefPubMed Lazzeri C, Valente S, Chiostri M, Attana P, Picariello C, Gensini GF. Impact of hypertension on short and long- term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes. Heart Vessels. 2012;27(4):370–6.CrossRefPubMed
3.
go back to reference Cecchi E, D’Alfonso MG, Chiostri M, Parigi E, Landi D, Valente S, et al. Impact of hypertension history on short and long-term prognosis in patients with acutemyocardial infarctioon treated with percutaneous angioplasty: comparison between STEMI and NSTEMI. High Blood Press Cardiovasc Prev. 2014;21(1):37–43.CrossRefPubMed Cecchi E, D’Alfonso MG, Chiostri M, Parigi E, Landi D, Valente S, et al. Impact of hypertension history on short and long-term prognosis in patients with acutemyocardial infarctioon treated with percutaneous angioplasty: comparison between STEMI and NSTEMI. High Blood Press Cardiovasc Prev. 2014;21(1):37–43.CrossRefPubMed
4.
go back to reference Lopez Minguez JR, Fuentes ME, Doblado MI, Merchán A, Martińez A, González R, et al. Prognostic role of systemic hypertension and diabetes mellitus in patients with unstable angina undergoing coronary stenting. Rev Esp Cardiol. 2003;56(10):987–94.CrossRefPubMed Lopez Minguez JR, Fuentes ME, Doblado MI, Merchán A, Martińez A, González R, et al. Prognostic role of systemic hypertension and diabetes mellitus in patients with unstable angina undergoing coronary stenting. Rev Esp Cardiol. 2003;56(10):987–94.CrossRefPubMed
5.
go back to reference Hoebers LP, Claessen BE, Woudstra P, DVries JH, Wykrzykowska JJ, Vis MM, et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin–treated diabetes mellitus. Eurointervention. 2014;10(1):90–6.CrossRefPubMed Hoebers LP, Claessen BE, Woudstra P, DVries JH, Wykrzykowska JJ, Vis MM, et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin–treated diabetes mellitus. Eurointervention. 2014;10(1):90–6.CrossRefPubMed
6.
go back to reference Klempfner R, Elis A, Matezky S, Keren G, Roth A, Finkelstein A, et al. Temporal trends in management and outcome of diabetic and nn-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: insight from the ACS Israeli Survey (ACSIS) 2000–2010. Int J Cardiol. 2015;179:546–51.CrossRefPubMed Klempfner R, Elis A, Matezky S, Keren G, Roth A, Finkelstein A, et al. Temporal trends in management and outcome of diabetic and nn-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: insight from the ACS Israeli Survey (ACSIS) 2000–2010. Int J Cardiol. 2015;179:546–51.CrossRefPubMed
7.
go back to reference Park KH, Ahn Y, Jeong MH, Chae SC, Hur SH, Kim YJ, et al. Different impact of diabetes mellitus on in-hospital and 1-year mortality in patients with acute myocardial infarction intervention: results from the Koran Acute Myocardial Infarction Registry. Korean J Intern Med. 2012;27(2):180–8.CrossRefPubMedPubMedCentral Park KH, Ahn Y, Jeong MH, Chae SC, Hur SH, Kim YJ, et al. Different impact of diabetes mellitus on in-hospital and 1-year mortality in patients with acute myocardial infarction intervention: results from the Koran Acute Myocardial Infarction Registry. Korean J Intern Med. 2012;27(2):180–8.CrossRefPubMedPubMedCentral
8.
go back to reference Jensen LO, Maeng M, Thayssen P, Tilsted HH, Terkelsen CJ, Kaltoft A, et al. Influence of diabetes on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(5):629–35.CrossRefPubMed Jensen LO, Maeng M, Thayssen P, Tilsted HH, Terkelsen CJ, Kaltoft A, et al. Influence of diabetes on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(5):629–35.CrossRefPubMed
9.
go back to reference Kahn MB, Cubbon RM, Mercer B, Wheatcroft AC, Gherardi G, Aziz A, et al. Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segmenty elevatin myocardial infarction in the contemporary era. Diab Vas Dis Res. 2012;9(1):3–9.CrossRef Kahn MB, Cubbon RM, Mercer B, Wheatcroft AC, Gherardi G, Aziz A, et al. Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segmenty elevatin myocardial infarction in the contemporary era. Diab Vas Dis Res. 2012;9(1):3–9.CrossRef
10.
go back to reference Lee MG, Jeong MH, Lee KH, Park SH, Sim DS, Yoon HJ, et al. Prognostic impact of diabetes and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. J Cardiol. 2012;60(4):257–63.CrossRefPubMed Lee MG, Jeong MH, Lee KH, Park SH, Sim DS, Yoon HJ, et al. Prognostic impact of diabetes and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. J Cardiol. 2012;60(4):257–63.CrossRefPubMed
11.
go back to reference Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of ReStenosis with tranilast and its outcome (PRESTO) trial. Circulation. 2004;109(4):476–80.CrossRefPubMed Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of ReStenosis with tranilast and its outcome (PRESTO) trial. Circulation. 2004;109(4):476–80.CrossRefPubMed
12.
go back to reference Laskey WK, Selzer F, Vlachos HA, Johnston J, Jacobs A, King 3rd SB, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol. 2002;90(10):1062–7.CrossRefPubMed Laskey WK, Selzer F, Vlachos HA, Johnston J, Jacobs A, King 3rd SB, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol. 2002;90(10):1062–7.CrossRefPubMed
13.
go back to reference Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. SYNTAX investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.CrossRefPubMed Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. SYNTAX investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.CrossRefPubMed
14.
go back to reference American Diabetic Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care. 2013;36 Supplement 1:S67-S74. American Diabetic Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care. 2013;36 Supplement 1:S67-S74.
15.
go back to reference National Kidney Foundation, Kidney Disease Outcome Quality Initiative (K/DOQI). Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kid Dis. 2003;42:S1–201. National Kidney Foundation, Kidney Disease Outcome Quality Initiative (K/DOQI). Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kid Dis. 2003;42:S1–201.
16.
go back to reference Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.CrossRefPubMed Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.CrossRefPubMed
17.
go back to reference Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128–37.CrossRefPubMed Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128–37.CrossRefPubMed
18.
go back to reference Poulter NR, Wedel H, Dahlöf B, Server PS, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907–13.CrossRefPubMed Poulter NR, Wedel H, Dahlöf B, Server PS, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907–13.CrossRefPubMed
19.
go back to reference Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–58.CrossRefPubMed Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–58.CrossRefPubMed
20.
go back to reference Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J. 2006;27(7):796–801.CrossRefPubMed Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J. 2006;27(7):796–801.CrossRefPubMed
21.
go back to reference Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.CrossRefPubMed Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.CrossRefPubMed
22.
go back to reference Heart Protection Study collaborativer Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef Heart Protection Study collaborativer Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
23.
go back to reference The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57. The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57.
Metadata
Title
Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention
Authors
Mao-Jen Lin
Chun-Yu Chen
Hau-De Lin
Han-Ping Wu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0454-5

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue